费城染色体样急性淋巴细胞白血病
费城染色体样急性淋巴细胞白血病(Ph样ALL)又称BCR-ABL1样ALL,是与Ph阳性ALL基因表达谱显著重叠、提示激酶信号激活的高危亚型。Ph样ALL含多种激活激酶和细胞因子受体信号的基因组改变,可分为涉及ABL1、ABL2、CSF1R和PDGFRB的ABL类融合及激活JAK/STAT信号的CRLF2、JAK2和EPOR改变等亚类。近期研究有助于明确其基因组全景、随年龄变化、相关临床特征与结局及遗传危险因素;临床前研究和个案报告显示靶向抑制剂在特定亚类有活性,精准医学试验已启动。
要点
- Ph样ALL又称BCR-ABL1样ALL,基因表达谱与Ph阳性ALL显著重叠,提示激酶信号激活。
- Ph样ALL含多种激活激酶和细胞因子受体信号的基因组改变,可分为ABL类融合及JAK/STAT信号改变等亚类。
- 临床前研究和个案报告显示靶向抑制剂在特定Ph样ALL亚类有活性,精准医学试验已启动。
核心结论
- Ph样ALL是与Ph阳性ALL基因表达谱显著重叠、提示激酶信号激活的高危亚型,含多种激活激酶和细胞因子受体信号的基因组改变。
- 临床前研究和个案报告显示靶向抑制剂在特定Ph样ALL亚类有活性,精准医学试验已针对该高危亚组启动。
研究设计与样本
- 原文为综述,检索范围未报告。
主要发现
- Ph样ALL病例含多种激活激酶和细胞因子受体信号的基因组改变,而非由BCR-ABL1融合定义。
- ABL类融合涉及ABL1、ABL2、CSF1R和PDGFRB,表型模拟BCR-ABL1。
- CRLF2、JAK2和EPOR改变激活JAK/STAT信号。
- 其他基因组改变激活BLNK、DGKH、FGFR1、IL2RB、LYN、NTRK3、PDGFRA、PTK2B、TYK2及RAS信号通路。
- 近期研究有助于明确Ph样ALL的基因组全景及其随年龄谱的变化、相关临床特征与结局和遗传危险因素。
关键数值与推荐
- Ph样ALL又称BCR-ABL1样ALL,其基因表达谱与Ph阳性ALL显著重叠并提示激酶信号激活。
- Ph样ALL的基因组改变可分为ABL类融合(ABL1、ABL2、CSF1R、PDGFRB)和激活JAK/STAT信号的改变(CRLF2、JAK2、EPOR)等主要亚类。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as BCR-ABL1-like ALL, is a high-risk subset with a gene expression profile that shares significant overlap with that of Ph-positive (Ph+) ALL and is suggestive of activated kinase signaling. Although Ph+ ALL is defined by BCR-ABL1 fusion, Ph-like ALL cases contain a variety of genomic alterations that activate kinase and cytokine receptor signaling. These alterations can be grouped into major subclasses that include ABL-class fusions involving ABL1, ABL2, CSF1R, and PDGFRB that phenocopy BCR-ABL1 and alterations of CRLF2, JAK2, and EPOR that activate JAK/STAT signaling. Additional genomic alterations in Ph-like ALL activate other kinases, including BLNK, DGKH, FGFR1, IL2RB, LYN, NTRK3, PDGFRA, PTK2B, TYK2, and the RAS signaling pathway. Recent studies have helped to define the genomic landscape of Ph-like ALL and how it varies across the age spectrum, associated clinical features and outcomes, and genetic risk factors. Preclinical studies and anecdotal reports show that targeted inhibitors of relevant signaling pathways are active in specific Ph-like ALL subsets, and precision medicine trials have been initiated for this high-risk ALL subset.
引用
- Tasian SK, Loh ML, Hunger SP, et al. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017. PMID: 28972016. doi:10.1182/blood-2017-06-743252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。